...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors
【24h】

Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors

机译:新型2,4-二酰基甲基嘧啶衍生物的合成和抗肿瘤效果携带N-(3-吡啶基甲基)脲部分作为促进淋巴瘤激酶抑制剂

获取原文
获取原文并翻译 | 示例

摘要

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for development of various tumor types. In this study, we synthesized a series of novel 2,4-diarylaminopyrimidine derivatives possessing a unique N-(3-pyridinylmethyl)urea moiety as ALK inhibitors. The most promising analog 5m bearing a 3-methoxy-4-morpholinophenyl substituent significantly inhibited proliferation of ALK positive H3122 and Karpas-299 cells with IC50 values about 10 nM, which were comparable with positive control LDK378. Compound 5m suppressed phosphorylation of ALK and its downstream proteins, and showed low cytotoxicity on normal human primary fibroblast cells (BJ cells). The binding mode of 5m was proposed by docking simulation, which explains the important role of N-(3-pyridinylmethyl)urea moiety. Furthermore, compound 5m exhibited favorable liver microsomal stability and significant efficacy in H3122 xenograft mice model. Interestingly, compound 5m also showed broader anti-proliferative activity on other human tumor cell lines, which was different from other ALK inhibitors. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:间变性淋巴瘤激酶(ALK)是受体酪氨酸激酶负责各种肿瘤类型的发展。在这项研究中,我们合成了具有独特的N-(3-吡啶基甲基)脲部分作为ALK抑制剂的一系列新颖的2,4- diarylaminopyrimidine衍生物。最有前途的类似物5米轴承3-甲氧基-4-吗啉代取代基ALK阳性H3122和KARPAS-299细胞以约10nM的IC 50个值,这是与阳性对照LDK378可比显著抑制增殖。化合物5米抑制ALK及其下游蛋白质的磷酸化,并表现出对正常的人原代成纤维细胞(BJ细胞)低的细胞毒性。 5米的结合模式,提出了通过对接模拟,这解释了N-(3-吡啶基甲基)脲基部分的重要作用。此外,化合物5米表现出H3122异种移植小鼠模型有利肝微粒体稳定性和显著功效。有趣的是,化合物5米也表现出对其他人肿瘤细胞系,这是从其它ALK抑制剂,更广泛的不同的抗增殖活性。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号